100 Most Influential People in Healthcare – 2018

Ubl has a front-row seat in the debate on skyrocketing drug prices. In June, after filing comments on the Trump administration's blueprint for addressing drug prices, Ubl said, "Our industry agrees with the administration that the status quo is not working in the best interest of patients, and our healthcare system needs to change." PhRMA is also in a lobbying fight with providers over the 340B drug discount program, with both sides investing heavily in trying to influence lawmakers.